Miltenyi Bioindustry

Executive Summary

Miltenyi Bioindustry, a division of Miltenyi Biotec, is a German CDMO offering end-to-end services for cell and gene therapy development and manufacturing. Leveraging proprietary automated platforms, the company supports clients from pre-clinical phases through commercial launch, specializing in lentiviral vector production and GMP cell therapy manufacturing. With a strong foundation in bioprocessing and a reputation for quality, Miltenyi Bioindustry is well-positioned to capture growing demand from the cell and gene therapy pipeline. The company's integrated approach reduces timelines and risks for partners, making it a key player in the outsourced manufacturing space. As the cell therapy market expands, Miltenyi Bioindustry's ability to scale and innovate will be critical to its growth.

Upcoming Catalysts (preview)

• Q3 2026Expansion of manufacturing capacity at Bergisch Gladbach facility80% success
• Q4 2026Strategic partnership with a major cell therapy developer for commercial supply60% success
• Q2 2027Launch of next-generation automated manufacturing platform70% success